You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKT inhibitor

Showing 1 - 25 of 7,714
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Breast Cancer Trial in Boston (Ipatasertib, Fulvestrant, Aromatase Inhibitor)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Oct 25, 2021

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Seborrheic Keratosis Trial in Santa Tecla (SM-020)

Recruiting
  • Seborrheic Keratosis
  • Santa Tecla, La Libertad, El Salvador
    Zepeda Dermatologia
Aug 20, 2022

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022

Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,

Not yet recruiting
  • Colorectal Adenomatous Polyp
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
  • +4 more
Jan 3, 2023

Triple Negative Breast Cancer Trial in Madison (Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Akt/ERK Inhibitor ONC201
  • Methionine-Restricted Diet
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Feb 11, 2022

Estrogen Receptor Positive Breast Cancer Trial in United Kingdom (AZD5363, Placebo, Fulvestrant)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Manchester, Greater Manchester, United Kingdom
  • +20 more
Aug 5, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced

Recruiting
  • Head and Neck Carcinoma of Unknown Primary
  • +24 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Aug 6, 2022

Ovarian Cancer Trial in Tampa (Triciribine, Carboplatin)

Terminated
  • Ovarian Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 22, 2020

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in United States

Completed
  • Endometrial Adenocarcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Hartford, Connecticut
  • +21 more
Oct 13, 2020

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma Trial in Los Angeles (drug, radiation,

Withdrawn
  • Recurrent Glioblastoma
  • +3 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 10, 2021

Langerhans Cell Histiocytosis Trial in United States (GSK2110183)

Completed
  • Langerhans Cell Histiocytosis
  • Baltimore, Maryland
  • +4 more
Sep 3, 2020

Advanced Cancer Trial in Newcastle, Sutton (olaparib, AZD5363)

Completed
  • Advanced Cancer
  • Newcastle, Newcastle Upon Tyne, United Kingdom
  • +1 more
Jan 31, 2020

Melanoma Trial in San Francisco, New York (Trametinib (GSK1120212), GSK2141795)

Completed
Has Results
  • Melanoma
  • San Francisco, California
  • +1 more
Jan 31, 2020

Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Akt Inhibitor GSK2141795,

Completed
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Akt Inhibitor GSK2141795
  • +2 more
  • Washington, District of Columbia
  • +7 more
Aug 27, 2019

Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Trial in France, United Kingdom, United States (Laboratory Biomarker

Completed
Has Results
  • Recurrent Uveal Melanoma
  • Stage IV Uveal Melanoma AJCC v7
  • Laboratory Biomarker Analysis
  • +3 more
  • Atlanta, Georgia
  • +6 more
Feb 14, 2020